GlaxoSmithKline Current Ratio 2006-2018 | GSK

Current and historical current ratio for GlaxoSmithKline (GSK) from 2006 to 2018. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. GlaxoSmithKline current ratio for the three months ending December 31, 2018 was 0.75.
GlaxoSmithKline Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2018-12-31 $22.59B $30.02B 0.75
2018-09-30 $22.70B $23.97B 0.95
2018-06-30 $23.20B $24.77B 0.94
2018-03-31 $22.85B $37.47B 0.61
2017-12-31 $20.50B $34.24B 0.60
2017-09-30 $23.12B $35.92B 0.64
2017-06-30 $21.01B $36.81B 0.57
2017-03-31 $20.79B $23.23B 0.90
2016-12-31 $22.65B $25.75B 0.88
2016-09-30 $23.13B $23.82B 0.97
2016-06-30 $24.22B $25.98B 0.93
2016-03-31 $22.68B $19.94B 1.14
2015-12-31 $25.36B $20.52B 1.24
2015-09-30 $26.33B $19.77B 1.33
2015-06-30 $27.75B $21.13B 1.31
2015-03-31 $31.63B $23.93B 1.32
2014-12-31 $24.19B $21.91B 1.10
2014-09-30 $24.83B $25.52B 0.97
2014-06-30 $22.81B $20.62B 1.11
2014-03-31 $21.92B $19.31B 1.14
2013-12-31 $23.83B $21.40B 1.11
2013-09-30 $20.88B $19.89B 1.05
2013-06-30 $20.64B $19.17B 1.08
2013-03-31 $21.93B $18.66B 1.18
2012-12-31 $21.70B $21.90B 0.99
2012-09-30 $21.32B $22.06B 0.97
2012-06-30 $27.34B $24.39B 1.12
2012-03-31 $25.57B $22.83B 1.12
2011-12-31 $25.94B $24.08B 1.08
2011-09-30 $26.43B $21.13B 1.25
2011-06-30 $26.62B $22.23B 1.20
2011-03-31 $26.90B $20.99B 1.28
2010-12-31 $24.80B $19.51B 1.27
2010-09-30 $26.03B $17.42B 1.49
2010-06-30 $25.48B $17.91B 1.42
2010-03-31 $28.66B $18.98B 1.51
2009-12-31 $27.51B $18.98B 1.45
2009-09-30 $28.47B $18.26B 1.56
2009-06-30 $23.61B $13.99B 1.69
2009-03-31 $24.40B $14.02B 1.74
2008-12-31 $32.03B $18.58B 1.72
2008-09-30 $28.37B $16.69B 1.70
2008-06-30 $28.95B $16.30B 1.78
2008-03-31 $24.94B $18.47B 1.35
2007-12-31 $27.27B $20.70B 1.32
2007-09-30 $23.00B $18.25B 1.26
2007-06-30 $21.78B $14.31B 1.52
2007-03-31 $14.22B $9.75B 1.46
2006-12-31 $20.26B $13.39B 1.51
2006-09-30 $22.30B $13.67B 1.63
2006-06-30 $23.12B $15.07B 1.53
2006-03-31 $24.44B $16.38B 1.49
2005-12-31 $24.00B $17.32B 1.39
2005-09-30 $23.86B $15.96B 1.50
2005-06-30 $22.79B $15.66B 1.46
2005-03-31 $21.51B $17.76B 1.21
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $98.852B $41.140B
GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $368.953B 16.73
Pfizer (PFE) United States $234.424B 13.13
Merck (MRK) United States $197.334B 16.86
Novartis AG (NVS) Switzerland $176.507B 15.01
Eli Lilly (LLY) United States $119.326B 20.72
Novo Nordisk (NVO) Denmark $118.242B 19.13
AbbVie (ABBV) United States $114.422B 9.81
Sanofi (SNY) France $103.609B 12.79
AstraZeneca (AZN) United Kingdom $98.276B 11.21
Bristol-Myers Squibb (BMY) United States $74.378B 11.44